The Impact of Nonadherence to Inhaled Long-Acting β 2 -Adrenoceptor Agonist/Corticosteroid Combination Therapy on Healthcare Costs in Difficult-to-Control Asthma

By O'Neill Ciaran   Gamble Jacqui   Lindsay John T.   Heaney Liam G.  

Pharmaceutical Medicine, Vol. 25, Iss. 6, 2011-12 ,pp. : 379-385

Adis International

Access to resources Recommend Favorite

Inhaled corticosteroids plus long-acting &bgr;₂-agonists as a combined therapy in asthma

By García-Marcos Luis   Schuster Antje   Barroso Nicolás Cobos  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 1, 2003-01 ,pp. : 23-39

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma

By Kim Dennis   Glaum Mark   Lockey Richard  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 8, 2009-08 ,pp. : 933-940

Informa Healthcare

Access to resources Recommend Favorite

The effects of formoterol, a long-acting 2 -adrenoceptor agonist, on mucociliary activity

By Lindberg S.   Khan R.   Runer T.  

European Journal of Pharmacology, Vol. 285, Iss. 3, 1995-10 ,pp. : 275-280

Elsevier

Access to resources Recommend Favorite

Combination Therapy of Inhaled Corticosteroids and Long-Acting &bgr;2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease

By  

Current Pharmaceutical Design, Vol. 10, Iss. 28, 2004-11 ,pp. : 3547-3560

Bentham Science Publishers

Access to resources Recommend Favorite